← All trials
NCT04570085
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Nov 30, 2023
- Completion date
- Nov 30, 2023
- First posted
- Sep 30, 2020
- Last posted
- Oct 20, 2020
- Enrollment
- 248
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LilleLead sponsor
- University of LilleOverall official - principal investigator
- Groupement Interrégional de Recherche Clinique et d'Innovation EstCollaborator
- Government of FranceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.